Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
NCT00411645 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
- Lead sponsor
- Shire
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 13, 2006
- Completion date
- May 23, 2009
- Enrollment
- 681 (actual)
- Sites
- 97
Conditions
As the registry lists them; a condition with its own page is linked.